Latest News and Press Releases
Want to stay updated on the latest news?
-
Describes mechanism which sensitizes cancer cells to radiotherapy Supports recent results showing a near doubling of median overall survival observed in patients with pancreatic cancer by combining...
-
Phase 3 ROMAN trial in severe oral mucositis expected to complete enrollment in 1H21; topline data expected in 2H21 Recently announced near doubling of median overall survival observed in...
-
MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
-
Near double the median overall survival observed in patients receiving Galera’s dismutase mimetic + SBRT versus placebo + SBRT, showing strong therapeutic potential Improvements versus placebo also...
-
Pivotal Phase 3 ROMAN Trial in Severe Oral Mucositis on Track for Completion of Enrollment in 1H21; Topline Data Readout in 2H21 Anticipate Final Data Readout from Locally Advanced Pancreatic...
-
MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
-
MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
-
Presented Promising Interim Data from Placebo-controlled Pilot Dismutase Mimetic SBRT Combination Trial for Pancreatic Cancer Announced Planned Phase 2b GC4711 SBRT Combination Trial for Pancreatic...
-
MALVERN, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
-
Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting First trial to evaluate anti-cancer activity...